LUPIN LTD SHARE PRICE [LIVE]

  
NSE: LUPIN
776.00
BSE: 500257
775.35
To view real time prices Login to your account
OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
BSE Click here to view BSE data
Live Chart
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality

Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
-11.38%
Sector
-6.52%
Sensex
7.54%
Underperformed both Sector by -4.86% and Sensex by -18.92%
IndustryPharma
MARKET CAP (Large Cap Stock)Rs 34,712 Cr
PE (TTM) 512.85
DIVIDEND YIELD 0.52%
PE Ratio517.05
Price to Book Value2.97
EV to EBIT97.17
EV to EBITDA29.09
EV to Capital Employed2.55
EV to Sales2.42
PEG Ratio4.69
Dividend Yield0.52%
ROCE (Latest)2.62%
ROE (Latest)0.57%
NameSep 22Jun 22
Promoters (Change:0.01) 47.11%47.1%
FIIs (Change:-0.46) 13.81%14.27%
Mutual Funds (Change:0.58) 16.44%15.86%
Insurance Companies (Change:0.14) 10.96%10.82%
Other DIIs (Change:-0.27) 0.23%0.5%
Non Institution (Change:0.00) 11.45%11.45%

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in LUPIN LTD

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

LUPIN News

Frequently Asked Questions

What is the Share price of LUPIN LTD. (LUPIN)?

LUPIN LTD. (LUPIN) share price as of December 2, 2022, on NSE is Rs 776.00 (NSE) and Rs 775.35 (BSE) on BSE.

Can I buy LUPIN LTD. (LUPIN) shares?

Yes, You can buy LUPIN LTD. (LUPIN) shares by opening a Demat account with Angel One.

How do I buy LUPIN LTD. (LUPIN) from Angel One?

LUPIN LTD. (LUPIN) share can be brought through the following modes:
  1. Direct investment: You can buy LUPIN LTD. (LUPIN) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to LUPIN LTD. (LUPIN) shares.

In which sector do LUPIN LTD. (LUPIN) belong?

LUPIN LTD. (LUPIN) belongs to Pharma.

What is the total Asset of Lupin?

The total asset of Lupin is Rs. 21,651 crores.

What is the main business of Lupin?

The main business of Lupin is to manufacture a wide range of branded and generic drug formulations. Established in 1968, Lupin is an innovation-led transnational pharmaceutical company in India which also produces active pharmaceutical ingredients (APIs).

Who are the promoters of Lupin?

Some of the key promoters of Lupin include Lupin Investments Pvt Ltd, Manju D Gupta, Nilesh D Gupta, Anuja Gupta, Desh Bandhu Gupta HUF, Vinita Gupta, Richa Gupta, Kavita Gupta, Veda Nilesh Gupta, and Neel Deshbandhu Gupta.

What are the Subsidiaries that comes under Lupin?

Some of the subsidiaries that come under Lupin are Lupin Inc., USA, Lupin Pharmaceuticals, Inc., USA, Pharma Dynamics (Proprietary) Limited, South Africa, Hormosan Pharma GmbH, Germany, Multicare Pharmaceuticals Philippines, Inc., Generic Health Pty Limited, Australia, and Nanomi B.V., Netherlands.

About LUPIN

Today's live share price for LUPIN LTD is NSE: ₹ 776.00, BSE: ₹ 775.35 with a current market capitalization of .

Lupin Ltd is an India-based pharmaceutical company. The company produces a range of generic and branded formulations and Active Pharmaceutical Ingredients (APIs). The company`s product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments. The company`s drug delivery platforms include Bioadhesive/Gastroretentive Extended Release, Laser-Drilled Extended Release, Matrix/Coated Extended Release, Taste Masking Technologies and Improved Bioavailability through Solubilizationand Nano-particle technology. Their APIs products include antibiotics, Antibiotics, ANTI-TB, Cardiovasculars, Central Nervous System, Analegesics and ANTI-GOUT. Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep. In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, they formed Lupin Pharmaceuticals Inc. USA, for trading, marketing and developmental activities in the US. In the year 2006, the company set up a new facility at Jammu. In the year 2007, the company acquired Vadodara based Rubamin Laboratories Ltd (rechristened to Novodigm Ltd). Also, they acquired Kyowa Pharmaceutical Industry Company Limited, a leading Generic Company in Japan. They started commercial production at their newly finished dosage facility at Jammu. Also, they set a new finished dosage facility at Indore. During the year 2008-09, the company expanded their product basket in Japan-Kyowa and received ten products approval from Ministry of Health & Labour Welfare, Japan. They acquired 100% stake in Hormosan Pharma GmbH, a generic company in Germany. Also, they acquired 36.65% stake in Generic Health Pty Ltd., in Australia, 60% stake in Pharma Dynamics in South Africa and 51% stake in Multicare Pharmaceuticals Philippines Inc in Philippines. During the year 2009-10, Lupin (Europe) Ltd, UK and Lupin Pharma Canada Ltd, Canada were incorporated on June 5, 2009 and June 18, 2009 respectively. Lupin Holding B V, the Netherlands transferred their holdings in Max Pharma Pty Ltd, Australia, a wholly owned subsidiary of the company to Generic Healthy Pty Ltd, Australia, an associated of the company upon which Max Pharma Pty Ltd ceased to be a subsidiary of the company with effect from May 31, 2009. In January 2010, as per the scheme of amalgamation, Novodigm Ltd, Lupin Pharmacare Ltd and Lupin Herbal Ltd, wholly owned subsidiaries of the company were amalgamated with the company with effect from April 1, 2009. In August 23, 2010, the company incorporated Lupin Mexico SA de CV, Mexico as a subsidiary company. The company increased their stake in Generic Health Pty Ltd., (Generic), Australia, from 49.91% to 76.65% and thus Generic became a subsidiary of the company with effect from September 27, 2010. Consequently, Bellwether Pharma Pty Ltd., Australia, Generic Health Inc., U.S.A. and Max Pharma Pty Ltd., Australia, which were subsidiaries of Generic, became subsidiaries of the company with effect from September 27, 2010. The company incorporated Lupin Philippines, Inc., Philippines and Lupin Healthcare Ltd., India, as subsidiaries on December 20, 2010 and March 17, 2011 respectively. In June 2011, the company`s Generic Healthy Pty Ltd acquired worldwide rights for the Goanna Brand and the complete range of premium therapeutic oils, rubs and ointments marketed under the brand. In July 2011, the company entered into a research and development agreement with Medicis Pharmaceutical Corporation (Medicis) to apply Lupin technologies to multiple therapeutic compounds. In November 2011, the company acquired I`rom Pharmaceuticals through their Japanese subsidiary. In 2012, the company receives Tentative Approval for Generic Glumetza Extended-Release Tablets. The company announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation. The company also launches Generic Geodon Capsules and Generic SEROQUEL Tablets during the year under review. In 2013, the company inaugurated new Plant at Nagpur. The company got Mahindra Samridhhi India Agri National Award for Bee keeping and Honey Production. In 2014, the company acquires Laboratorios Grin S.A. De C.V., Mexico; a Specialty Ophthalmic Company. The company enters the Latin American Market. The company also acquires Nanomi B.V. and enters Complex Injectables Space. The company receives FDA Approval for Generic Actos Tablets, and Generic Celebrex Capsules. In 2015, the company launches Generic DIOVANr Tablets. The company receives FDA Approval for Generic Vancocin Capsules. During the year under review, the company and Celon announce Strategic Development and Licensing Agreement for Generic Advair Diskus. The company and Rotary Join Hands to Combat Tuberculosis in Mumbai. The company introduces generic hypertension drug in US. The company receives various awards like UBM India Pharma Awards 2015, CNBC India Risk Management Awards etc. The company also acquires Biocom in Russia during the year under review.

Read more

Enjoy Zero Brokerage on Equity Delivery

Join our 1 Cr+ happy customers